4 Top Biotech Stocks To Buy For 2022

The biotechnology industry is currently focused on developing viable drugs, therapies, and devices with the integration of advanced technology to identify and treat chronic, life-threatening diseases. Also, the emergence of new coronavirus variants is incentivizing companies having a COVID-19 related product pipeline to conduct better research and develop new vaccines with high efficacy.

Moreover, regulatory approvals from FDA and EUA and growing investment and policy support from governments worldwide forecast a bright outlook for the biotech industry in the long run. Investor optimism in this space is evident from the First Trust NYSE Arca Biotechnology Index ETF’s (FBT) 2.9% gains over the past month versus the SPDR S&P 500 Trust ETF’s (SPY) negative returns. The global biotechnology market is expected to grow at 7.7% CAGR and reach $741.7 billion by 2026.

It might be wise to bet on fundamentally sound and undervalued biotech stocks Regeneron Pharmaceuticals, Inc. (REGN - Get Rating), Biogen Inc. (BIIB - Get Rating), United Therapeutics Corporation (UTHR - Get Rating), and Exelixis, Inc. (EXEL - Get Rating) now. The growing investments, advanced R&D, and impressive breakthroughs in the industry should enable these companies to profit substantially next year.

person holding silver and black hand tool

Photo by National Cancer Institute on Unsplash

Regeneron Pharmaceuticals, Inc. (REGN - Get Rating)

REGN is a biopharmaceutical company that develops, manufactures, and commercializes medicines to treat severe medical conditions. The company’s marketed products include EYLEA injection, Praluent injection, ARCALYST injection for subcutaneous use, and ZALTRAP injection for intravenous infusion, among others.

REGN has developed REGEN-COV, a single-dose antibody cocktail that has reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial and has stayed effective for up to eight months following the drug’s administration. REGEN-COV is currently FDA-approved for post-exposure prophylaxis (PEP) and is being considered for pre-exposure prophylaxis (PrEP).

On December 8, 2021, the New England Journal of Medicine published positive results from a pivotal Dupixent clinical trial in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Developed by REGN and Sanofi S.A. (SNY), Dupixent significantly reduced severe asthma attacks and, within two weeks, rapidly improved lung function in populations with an eosinophilic phenotype. Besides getting the FDA approval, the publication of its clinical trial is likely to help it gain wider recognition across the industry.

REGN’s total revenues for its fiscal third quarter, ended September 30, 2021, increased 50.5% year-over-year to $3.45 billion. The company’s income from operations came in at $1.85 billion, up 75.4% from its year-ago period. While its non-GAAP net income increased 84.4% year-over-year to $1.77 billion, its non-GAAP EPS increased 83.9% to $15.37. As of September 30, 2021, the company had $3.43 billion in cash and cash equivalents.

1 2 3 4
View single page >> |

Disclaimer: Riki nema disclaimer.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.